DRW Securities’s AbCellera Biologics ABCL Stock Holding History

DRW Securities’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14,000	Closed	-$90K	–	335
2023 Q2	$90K	Buy	+14,000	New	+$95.5K	﹤0.01%	315

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

DRW Securities's ABCL Position: Q3 2023 in Review

DRW Securities sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 14,000 shares — an estimated $90K sold.

DRW Securities first reported a position in ABCL in Q2 2023 and held it in 1 quarter. The position peaked at $90K in Q2 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

DRW Securities reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
DRW Securities sold 14,000 AbCellera Biologics shares in Q3 2023, an estimated $90K.
DRW Securities first reported a position in AbCellera Biologics in Q2 2023 and held it in 1 quarter.
DRW Securities's AbCellera Biologics position peaked at $90K in Q2 2023.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on DRW Securities's 13F filing for Q3 2023, filed 13 Nov 2023.